(Buserelin Acetate)

A Big triumph for medical society


Buserelin acetate is a synthetic peptide analog of the natural gonadotropin releasing hormone (GnRH/LHRH) with enhanced biological activity. CinnaFact® is the brand name for buserelin acetate produced by CinnaGen Co. Each vial of CinnaFact® contains 5.5 mg of injection solution (1 mg/mL; 5.5 ml)


  • CinnaFact® (Buserelin acetate) is indicated for advanced prostate cancer and endometriosis. CinnaFact® is also used for pituitary down-regulation during assisted reproductive technology (ART) procedures.

Important safety information

  • CinnaFact ® is contraindicated in pregnancy, breast-feeding, and patients with:

Hypersensitivity to buserelin or any component of the formulation and women with undiagnosed abnormal vaginal bleeding.

  • Anemia: Testosterone suppression is associated with the development of anemia.
  • CNS effects: May cause dizziness, which may impair physical or mental abilities.
  • Decreased bone density: Prolonged use of a luteinizing hormone releasing hormone (LHRH) agonist may cause decreased bone mineral density and possibly lead to osteoporosis and increased risk of skeletal bone fracture.
  • Disease fare: A transient exacerbation of the signs and symptoms of the disease process may be observed with the initiation of therapy in prostate cancer and endometriosis patients.
  •  Hypogonadism: Hypogonadism is an anticipated effect of androgen deprivation therapy.
  • Pituitary adenoma: The development of pituitary adenomas may rarely be seen with long-term therapy.
  • Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease.
  • Diabetes: Reduced glucose tolerance and loss of blood glucose control have been noted in rare cases.